A drug designed for something completely different might prevent cancer
At a major oncology conference in Chicago, three independent research teams have surfaced a quiet pattern in the data: medications already taken by millions for weight loss may be quietly reshaping the odds of breast cancer. The drugs—semaglutide and liraglutide—were born in the world of diabetes, yet they appear to carry effects that reach further into the body's chemistry than their designers intended. Science is now asking whether a medicine cabinet staple might also be a shield against one of the most common cancers in women.
- Three studies presented at ASCO converged on the same unexpected signal: GLP-1 drugs appear to reduce breast cancer risk by 30%, cut progression rates in half, and lift five-year survival odds by 6%.
- The findings land with urgency against a backdrop of over 320,000 expected U.S. breast cancer diagnoses this year and 40,000 projected deaths.
- Researchers caution that observational data cannot prove causation—the pattern is striking, but the mechanism remains incompletely understood.
- Beyond weight loss, these drugs appear to suppress inflammation and modulate immune function, suggesting their protective effects may operate through pathways no one originally mapped.
- Clinical teams at Penn, Cleveland Clinic, and Fox Chase are now pushing toward prospective randomized trials to determine whether the association is real and actionable.
- The question now sharpening into focus: can a drug already in millions of medicine cabinets be deliberately deployed as a cancer prevention tool for high-risk women?
This spring in Chicago, three research teams arrived at the American Society of Clinical Oncology's annual conference carrying findings that pointed in the same unexpected direction. Semaglutide and liraglutide—the GLP-1 medications behind Ozempic and Wegovy—may offer meaningful protection against breast cancer.
The first study, led by breast radiologist Elizabeth McDonald at the University of Pennsylvania, drew on health records from more than 110,000 overweight or obese women. Those who had taken GLP-1 drugs were about 30 percent less likely to develop breast cancer, even after controlling for age, BMI, breast density, and diabetes status. McDonald was clear that the study showed correlation, not cause—but her team is already designing a clinical trial to test the hypothesis directly.
A second study examined more than 12,000 patients already diagnosed with various cancers. Among those with breast cancer, only 10 percent of GLP-1 users saw their disease advance to a later stage, compared with 20 percent of patients on other diabetes medications. A third study, tracking nearly 137,500 breast cancer patients, found that those who took GLP-1 drugs continuously for at least three months had a 6 percent higher overall survival rate at five years.
What gives these findings particular weight is that GLP-1 drugs were never engineered with cancer in mind. They mimic appetite-suppressing hormones, but emerging research suggests they also dampen inflammation and reshape immune function—changes that may matter independently of weight loss. Oncologist Marcin Chwistek noted that the consistency of the signal across tumor types and the volume of data behind it now justifies moving toward prospective randomized trials.
With more than 320,000 American women expected to be diagnosed with breast cancer this year, the stakes of confirming—or disproving—this pattern are considerable. The next chapter belongs to the clinical trials now being designed to find out whether a drug already widely prescribed might also serve as a tool for prevention.
Three separate research teams presented findings this spring at the American Society of Clinical Oncology's annual conference in Chicago that suggest an unexpected benefit hiding inside medications millions of people are already taking for weight loss. The drugs in question—semaglutide and liraglutide, sold under brand names like Ozempic and Wegovy—were originally developed to treat diabetes. But as their use has exploded far beyond that original purpose, researchers have begun noticing something striking: people taking these GLP-1 medications seem to get sick less often, across a wide range of conditions. Now the evidence is pointing specifically at breast cancer.
The first study, led by Elizabeth McDonald, a breast radiologist at the University of Pennsylvania, examined health records from more than 110,000 women between the ages of 45 and 80 who were classified as overweight or obese. Between 2022 and 2025, roughly 14 percent of these women had been prescribed a GLP-1 medication at some point. When McDonald's team compared outcomes, they found that women who had taken these drugs were about 30 percent less likely to develop breast cancer than those who had not, even after accounting for age, race, ethnicity, body mass index, breast density, and whether they had diabetes. McDonald was careful to note that her study could not prove causation—only that the pattern existed. But she and her colleagues are now designing a clinical trial to test whether these drugs might actually prevent breast cancer in women at high risk.
A second study presented at the same conference examined outcomes in more than 12,000 people who had already been diagnosed with lung, breast, colorectal, or liver cancer. Among those with breast cancer specifically, the difference was stark. Ten percent of patients taking GLP-1 drugs saw their cancer progress to a more advanced stage, compared with 20 percent of patients taking a different diabetes medication. Mark David Orland, an oncologist at Cleveland Clinic's Taussig Cancer Institute and the lead author of that study, described the findings as early evidence that warranted further investigation across multiple cancer types.
The third study tracked nearly 137,500 breast cancer patients and found that those who took GLP-1 medications continuously for at least three months had a 6 percent higher overall survival rate five years after diagnosis. Taken together, the three studies paint a picture of a drug class that might reduce the risk of developing breast cancer, slow its progression if it does develop, and improve survival odds for those diagnosed.
What makes these findings particularly intriguing is that GLP-1 drugs were never designed to fight cancer. They work by mimicking natural hormones in the body that suppress appetite and promote weight loss. But emerging research suggests their effects run deeper. These medications appear to dampen inflammation and modulate immune function—changes that might matter as much as weight loss itself in protecting against cancer. Marcin Chwistek, an oncologist at Fox Chase Cancer Center, noted that GLP-1 receptor agonists have long been understood to do more than simply lower blood sugar. What's new, he said, is the consistency of the findings across different tumor types and the sheer volume of data supporting the pattern. That consistency, he argued, justifies launching prospective randomized clinical trials to determine whether the association is real.
The timing of these findings carries weight. This year, more than 320,000 women in the United States are expected to receive a breast cancer diagnosis, and roughly 40,000 will die of the disease. If GLP-1 medications can meaningfully reduce those numbers, the implications would be substantial. McDonald and her team are already moving forward with their trial, hoping to answer whether a drug already in millions of medicine cabinets might also serve as a tool for cancer prevention.
Citações Notáveis
Our study was observational and does not definitively confirm an association between GLP-1 medications and reduced breast cancer incidence. It does add to the growing body of evidence suggesting that it's worth investigating these weight loss drugs as potential cancer prevention tools.— Elizabeth McDonald, breast radiologist at University of Pennsylvania
GLP-1 receptor agonists have never been just glucose-lowering drugs. Their anti-inflammatory and immune-modulatory properties have long suggested broader effects. What's new here is the consistency across tumor types, and data this large and this consistent warrant a prospective randomized trial.— Marcin Chwistek, oncologist at Fox Chase Cancer Center
A Conversa do Hearth Outra perspectiva sobre a história
These studies are observational, not randomized trials. How confident should we be in what they're showing?
That's the right skepticism. Observational studies can show patterns but can't prove cause and effect. Someone taking a GLP-1 drug might also be more health-conscious overall, or have better access to screening. But what matters here is that three separate teams found similar signals, and the researchers themselves are saying the pattern is strong enough to warrant actual clinical trials.
So the weight loss itself—that's not the whole story?
Probably not. Yes, obesity is linked to worse breast cancer outcomes, so weight loss should help. But these drugs seem to do something else. They reduce inflammation and change how the immune system works. That might matter independently of the number on the scale.
If these trials confirm the benefit, how would doctors actually use this information?
That's still unclear. You wouldn't give a healthy woman an expensive injection just to prevent cancer—the side effects and costs don't justify that yet. But for women already at high risk, or maybe for women already diagnosed, it could become part of the treatment plan.
What's the timeline for knowing if this is real?
Clinical trials take years. But the researchers are moving fast because the preliminary signal is strong enough to justify it. We're probably looking at several years before we have definitive answers.
And if it works, what does that tell us about cancer in general?
It suggests that cancer isn't just about genetics or bad luck—it's also about the inflammatory and immune environment in your body. A drug designed for something completely different can apparently shift that environment in a protective direction. That opens up a lot of questions about what else might work.